Pharmaceutical

AbbVie and Xilio to collaborate on antibody-based immunotherapies

AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based immunotherapies.

Feb 13, 2025 - 06:00
AbbVie and Xilio to collaborate on antibody-based immunotherapies
AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based immunotherapies.
Read the original article

Tags:

Previous Article

Researchers Develop Versatile Biomimetic Liquid Metallic Leukocytes with Chemota...

Next Article

Abcuro secures $200m as it eyes approval for rare muscle disease drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biden nominates Monica Bertagnolli to head NIH

Biden nominates Monica Bertagnolli to head NIH

May 15, 2023

Merz strengthens its global footprint with botulinum approval in Australian market

Merz strengthens its global footprint with botulinum ap...

Nov 22, 2023

STAT+: How drug pricing reforms are affecting Bayer’s investments

STAT+: How drug pricing reforms are affecting Bayer’s i...

Jun 20, 2023